Clinical Trials Logo

High-grade B-cell Lymphoma clinical trials

View clinical trials related to High-grade B-cell Lymphoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04844086 Terminated - Clinical trials for Mantle Cell Lymphoma

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Start date: March 2, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients. Approximately 24 subjects will be enrolled and it is anticipated approximately 16 subjects will be infused at the varied doses of T cells.

NCT ID: NCT04358458 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Start date: March 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3009 dose to be tested in a larger group of patients and assess preliminary clinical activity of GEN3009. GEN3009 will be studied in a broad group of cancer patients, having different kinds of lymphomas. All patients will get GEN3009 either as a single treatment (monotherapy) or in combination with another antibody-candidate for treatment of cancer in the blood. The study consists of two parts: Part 1 tests increasing doses of GEN3009 ("escalation"), followed by Part 2 which tests the recommended GEN3009 dose from Part 1 ("expansion").

NCT ID: NCT03132584 Terminated - Clinical trials for Diffuse Large B Cell Lymphoma

Cyclophosphamide and Alemtuzumab In Lymphoma

Start date: July 30, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: - Cyclophosphamide - Alemtuzumab